Journal article

Generation of novel Id2 and E2-2, E2A and HEB antibodies reveals novel Id2 binding partners and species-specific expression of E-proteins in NK cells

Jai Rautela, Laura F Dagley, Tobias Kratina, Angaleena Anthony, Wilford Goh, Elliot Surgenor, Rebecca B Delconte, Andrew I Webb, Ngaire Elwood, Joanna R Groom, Fernando Souza-Fonseca-Guimaraes, Lynn Corcoran, Nicholas D Huntington



NK cells are cytotoxic lymphocytes with a key role in limiting tumour metastases. In mice, the NK cell lineage continually expresses high levels of the Inhibitor of DNA-binding 2 (Id2) protein and loss of Id2 is incongruous with their survival due to aberrant E-protein target gene activity. Using novel Id2 and E-protein antibodies that detect both mouse and human proteins, we have extensively characterised Id2 and E-protein expression in murine and human NK cells. We detected clear expression of E2 A and HEB, and to a lesser extent E2-2 in murine NK cells. In contrast HEB appears to be the major E-protein expressed in human NK cells, with minor E2-2 expression and surprisingly, no E2 A detec..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC) of Australia

Awarded by NHMRC

Awarded by National Breast Cancer Foundation (NBCF) Fellowship

Awarded by Priority-driven Collaborative Cancer Research Scheme

Awarded by Cancer Council of Victoria

Funding Acknowledgements

This work was supported by program and project grants from the National Health and Medical Research Council (NHMRC) of Australia (1124907, 1124784, 1049407, 1066770, 1057852, 1027472) and a fellowship (1124788) to N.D.H as well as an NHMRC Independent Research Institute Infrastructure Support scheme grant and a Victorian State Government Operational Infrastructure Scheme grant. F.S.F.S. was supported by a NHMRC Early Career Fellowship (1088703), a National Breast Cancer Foundation (NBCF) Fellowship (PF-15-008) and grant #1120725 awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Cure Cancer Australia with the assistance of Cancer Australia. N.D.H. is a recipient of a Melanoma Research Grant from the Harry J Lloyd Charitable Trust (USA), Melanoma Research Alliance (USA), Tour de Cure (AUS), the Ian Potter Foundation (AUS), Cancer Council of Victoria (1145730) and a CLIP grant from Cancer Research Institute (USA).